Phase 1 success for a trivalent vaccine for the equine encephalitis viruses

Affiliations

¹ QIMR Berghofer Medical Research Institute, Brisbane, Australia; Australian Infectious Disease Research Centre, GVN Centre of Excellence, Brisbane, Australia. Electronic address: Andreas.Suhrbier@qimrberghofer.edu.au.

Comment

Andreas Suhrbier. Lancet Infect Dis. 2022 Aug.

. 2022 Aug;22(8):1100-1102.

doi: 10.1016/S1473-3099(22)00122-0. Epub 2022 May 11.

¹ QIMR Berghofer Medical Research Institute, Brisbane, Australia; Australian Infectious Disease Research Centre, GVN Centre of Excellence, Brisbane, Australia. Electronic address: Andreas.Suhrbier@qimrberghofer.edu.au.

No abstract available

Conflict of interest statement

I declare no competing interests.

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Coates EE, Edupuganti S, Chen GL, Happe M, Strom L, Widge A, Florez MB, Cox JH, Gordon I, Plummer S, Ola A, Yamshchikov G, Andrews C, Curate-Ingram S, Morgan P, Nagar S, Collins MH, Bray A, Nguyen T, Stein J, Case CL, Kaltovich F, Wycuff D, Liang CJ, Carlton K, Vazquez S, Mascola JR, Ledgerwood JE; VRC 313 Study Team. Coates EE, et al. Lancet Infect Dis. 2022 Aug;22(8):1210-1220. doi: 10.1016/S1473-3099(22)00052-4. Epub 2022 May 11. Lancet Infect Dis. 2022. PMID: 35568049 Free PMC article. Clinical Trial.